HBA1c
Reading File
Finding Sources
Searching PubMed
HbA1c glycated hemoglobin diabetes
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Searching Images
HbA1c glycated hemoglobin diabetes diagnosis chart
Reading File
I now have comprehensive information from multiple authoritative textbooks. Here is a thorough overview of HbA1c:
HbA1c (Glycated Hemoglobin)
What Is It?
HbA1c is formed when glucose in the blood attaches non-enzymatically (a process called glycation, NOT glycosylation) to the epsilon-amino groups of lysyl residues and the alpha-amino group of the N-terminal valine of hemoglobin beta chains. Because this reaction is not enzyme-catalyzed, the amount of HbA1c formed is directly proportional to the ambient blood glucose concentration.
Since the average lifespan of a red blood cell is approximately 120 days, the HbA1c level reflects mean blood glucose over the preceding 8-12 weeks (roughly 3 months). - Harper's Illustrated Biochemistry, 32nd Ed
Biochemistry of Glycated Hemoglobin Species
| Name | Component |
|---|---|
| HbA1c | HbA with glucose attached to N-terminal valine of beta-chain (the specific form measured) |
| HbA1a1 | Fructose 1,6-diphosphate attached |
| HbA1a2 | Glucose 6-phosphate attached |
| HbA1b | Pyruvic acid attached |
| HbA1 | HbA1a + HbA1b + HbA1c combined |
| Pre-HbA1c | Unstable Schiff base (labile intermediate) - can falsely elevate results if not removed |
- Tietz Textbook of Laboratory Medicine, 7th Ed
Diagnostic Thresholds (ADA / WHO Criteria)
| Category | HbA1c (%) | HbA1c (mmol/mol) |
|---|---|---|
| Normal | < 5.7% | < 39 |
| Prediabetes | 5.7 - 6.4% | 39 - 47 |
| Diabetes | ≥ 6.5% | ≥ 48 |
- Goldman-Cecil Medicine, International Edition
HbA1c ≥ 6.5% is one of four diagnostic criteria for diabetes, alongside:
- Fasting plasma glucose ≥ 126 mg/dL
- Random plasma glucose ≥ 200 mg/dL with symptoms
- 2-hour OGTT glucose ≥ 200 mg/dL (75 g load)
All tests (except random glucose with classic symptoms) require confirmation on a separate day. - Robbins & Cotran Pathologic Basis of Disease
Glycemic Control Targets (HbA1c Therapy Goals)
| Patient Group | HbA1c Target |
|---|---|
| Most adults with diabetes | < 7% (53 mmol/mol) |
| Young/motivated, no hypoglycemia risk | ≤ 6.5% |
| Elderly with intact cognition | < 7 - 7.5% |
| Elderly with comorbidities / impaired cognition | < 8% (avoid hypoglycemia) |
The target should always be individualized based on age, comorbidities, hypoglycemia awareness, cardiovascular risk, and life expectancy. Tighter control was shown in ACCORD to increase mortality when targeting < 6%, underscoring the importance of personalization. - Harrison's Principles of Internal Medicine, 22nd Ed
Estimated Average Glucose (eAG) from HbA1c
The ADAG study established a linear correlation:
- eAG (mg/dL) = 28.7 × HbA1c − 46.7
- eAG (mmol/L) = 1.59 × HbA1c − 2.59
Example: HbA1c of 7% = eAG of approximately 154 mg/dL. The ADA and AACC recommend reporting both HbA1c and eAG. - Tietz Textbook of Laboratory Medicine, 7th Ed
Clinical Utility
- Diagnosis of diabetes - accepted as a diagnostic criterion since 2010
- Monitoring glycemic control - tracks long-term glucose management
- Predicting complications - higher HbA1c correlates with increased risk of microvascular complications (retinopathy, nephropathy, neuropathy)
- No fasting required - a major practical advantage over glucose-based tests
- Low biological variability and stable sample - Tietz Textbook of Laboratory Medicine, 7th Ed
Note: Point-of-care HbA1c devices should NOT be used for screening or diagnosis of diabetes (laboratory-grade methods required).
Reference Interval
- Normal (NGSP-certified method): 4 - 6% (20 - 42 mmol/mol)
- Small age-related increases (~0.1%/decade after age 30) have been observed but clinical significance is uncertain.
- Monitoring frequency: at least every 6 months for stable patients; more often if control is suboptimal.
Important Interferences and Limitations
| Factor | Effect on HbA1c |
|---|---|
| Hemolytic anemia / hemolysis | Falsely low (reduced RBC lifespan) |
| Sickle cell disease / hemoglobinopathies | Falsely low or unreliable (abnormal Hb variants) |
| Iron deficiency anemia | Falsely high (longer RBC lifespan) |
| Labile pre-HbA1c (Schiff base) | Falsely high if not removed before assay |
| Blood transfusions | Falsely low |
| Racial/ethnic variation | Blacks and non-Hispanic Whites may have higher HbA1c independent of glycemia |
In situations of altered RBC turnover or hemoglobinopathies, direct glucose measurement is preferred. - Goldman-Cecil Medicine
Specimen Collection
- Fasting is not required
- Collected in EDTA or oxalate + fluoride tubes
- Stable at 4°C for up to 1 week; at -70°C for at least 18 months
- Avoid repeated freeze-thaw cycles
- Heparinized samples should be assayed within 2 days
Recent Evidence
A 2025 systematic review and meta-analysis (PMID 41282290) confirmed that glycemic variability of HbA1c in type 2 diabetes is associated with significantly increased cardiovascular risk, reinforcing the clinical value of stable long-term glycemic control beyond just achieving a target number. A separate 2025 meta-analysis PMID 40640901 found that glycated albumin and fructosamine may have diagnostic utility in gestational diabetes where HbA1c is less reliable.
This is a shared conversation. Sign in to Orris to start your own chat.